National Institute for Clinical Excellence (NICE) Okays Bayer AG (BAY.F)'s Genentech Xarelto In Stroke Prevention  
3/30/2012 7:30:57 AM

The U.K.'s health-care cost-effectiveness body Friday recommended Bayer AG's (BAYN.XE) anti-clotting pill Xarelto as an option for stroke prevention and systemic embolism in people with a heart condition called atrial fibrillation, after requesting more information about it from the German chemical and pharmaceutical company. In January, the National Institute for Health and Clinical Excellence, or NICE, had asked Bayer for more information on Xarelto, also known as rivaroxaban, before deciding whether to recommend it for use by the U.K.'s publicly-funded National Health Service.